Zymeworks
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zymeworks and other ETFs, options, and stocks.About ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2).
CEOKenneth Harry Galbraith
CEOKenneth Harry Galbraith
Employees277
Employees277
HeadquartersMiddletown, Delaware
HeadquartersMiddletown, Delaware
Founded2003
Founded2003
Employees277
Employees277
ZYME Key Statistics
Market cap623.17M
Market cap623.17M
Price-Earnings ratio-5.05
Price-Earnings ratio-5.05
Dividend yield—
Dividend yield—
Average volume699.96K
Average volume699.96K
High today$9.00
High today$9.00
Low today$8.55
Low today$8.55
Open price$8.56
Open price$8.56
Volume455.95K
Volume455.95K
52 Week high$13.14
52 Week high$13.14
52 Week low$6.02
52 Week low$6.02
ZYME News
TipRanks 2d
Zymeworks Engages in Key Investor Conferences - TipRanks.com - TipRanksZymeworks (ZYME) has released an update. Zymeworks Inc., a clinical-stage biotech firm, has announced their participation in the Bank of America Securities Hea...
Yahoo Finance 2d
Zymeworks Announces Participation in Upcoming Investor Conferences - Yahoo FinanceZymeworks Inc. VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...
Yahoo Finance 4d
We Think Zymeworks Can Afford To Drive Business Growth - Yahoo FinanceJust because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com...
Analyst ratings
57%
of 7 ratingsBuy
57.1%
Hold
42.9%
Sell
0%